Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study

Blaszak, Michael; El-Masri, Maher M; Hirmiz, Khalid; Mathews, John; Omar, Abeer; Elfiki, Tarek; Gupta, Ritesh; Hamm, Caroline; Kanjeekal, Sindu M.; Kay, Amin; Kulkarni, Swati; Ghafoor, Akmal

doi:10.3892/mco.2017.1179

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most frequently encountered failures in pancreatic cancer treatment results from the distant-organ metastases at the very early stages of diagnosis, making surgery almost impossible. 29 Cancer metastasis starts with cell migration, followed by mesenchymal transition, intravasation into blood vessels, and extravasation to distant organs. 30 Therefore, inhibitors of cancer cell migration have a potential of suppressing the process of tumor metastasis formation.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

Ancistrolikokine E₃, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

et al. 2018

View full text Add to dashboard Cite

PANC-1 human pancreatic cancer cells are characterized by their ability to proliferate aggressively under hypovascular and hypoxic conditions in the tumor microenvironment, displaying a remarkable tolerance to nutrition starvation. The antiausterity strategy is a new approach in anticancer drug discovery aiming at the identification of potent agents that inhibit preferentially the survival of tumor cells during a limited supply of nutrients and oxygen. The new 5,8′-coupled naphthyldihydroisoquinoline alkaloid ancistrolikokine E 3 (4), isolated from the Congolese liana Ancistrocladus likoko, showed potent preferential cytotoxicity against PANC-1 cells under nutrient-deprived conditions, with a PC 50 value of 2.5 μM, without exhibiting toxicity in normal, nutrient-rich medium. The compound was found to induce dramatic alterations in cell morphology, leading to cell death. Moreover, it inhibited significantly PANC-1 cell migration and colony formation in a concentration-dependent manner. This study on 4 provides the first live evidence of the effect of a naphthyldihydroisoquinoline alkaloid against PANC-1 cells in nutrient-deprived medium. Mechanistic investigations conducted suggest that compound 4 is a potent inhibitor of the activation of the Akt/mTOR pathway. Furthermore, it inhibited the expression levels of the key autophagy regulators Atg5, Atg12, Beclin-1, LC3-I, and LC3-II. The results demonstrated that ancistrolikokine E 3 (4) is a potent early-stage inhibitor of the autophagy pathway in PANC-1 human pancreatic cancer cells. Ancistrolikokine E 3 (4) and related naphthylisoquinoline alkaloids are promising potential lead compounds for anticancer drug development based on the antiausterity strategy.

show abstract

Section: ■ Results and Discussionmentioning

confidence: 99%

Ancistrolikokine E₃, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, the level of recurrences after surgery is still high, both local and systemic. Adjuvant treatment is used to improve survival prospects and involves chemotherapy, radiation and / or combined modalities, but there are still controversies regarding the treatment of choice [4].…”

Section: Introductionmentioning

confidence: 99%

miR-203a-3p and MMP-2 protein are highly expressed in circulating tumor cells from patients with pancreatic carcinoma

Tarazona¹,

Abdallah²,

Flores³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: to explore the morphological, molecular and phenotypical characteristics of circulating tumor cells (CTCs) from blood of patients with pancreatic carcinoma, and to correlate the findings with response to treatment, progression-free survival, overall survival (OS) and deep vein thrombosis (DVT). Methods: peripheral blood (10mL) was analyzed before the beginning of treatment, and after 60 and 120 days. CTCs were detected by ISET® and characterized by immunocytochemistry. For miRNAs analysis, peripheral leukocytes from the same patients and healthy individuals (controls) were collected in parallel at baseline. The expression of miRNAs was evaluated (in pool) using TaqMan™ Array Human MicroRNA Cards v2.0. Results: there were included 9 patients. The proteins MMP2 and TGFβ-RI were highly expressed (77.7%) in CTCs at baseline; at the first follow-up, MMP2 was predominant (80%) and at second follow-up, MMP2 and vimentin were predominant (50%). Circulating tumor microemboli (CTM) were found in two patients and both presented DVT. The miR-203a-3p was highly expressed in CTCs. miR-203a-3p is involved in the stimulation of epithelial-to-mesenchymal transition (EMT) and related to worse OS in pancreatic cancer (TCGA data). Conclusion: Due to the low number of patients and short follow-up, we did not observe a correlation between CTCs and response to treatment. However, there was a correlation between CTM and DVT as also miR-203a-3p was highly expressed in CTCs, corroborating the findings of EMT proteins. This study opens perspectives concerning the dynamic change in the pattern of proteins expressed along treatment and the use of miRNAs as new targets in pancreatic carcinoma.

show abstract

“…The survival among patients who receive only best supportive care is 1.1-2.9 months (45,112,(132)(133)(134).…”

Section: Performance Statusmentioning

confidence: 99%

“…Comparatively, the survival of PDAC patients treated with only BSC is very short. Recent studies estimate the mOS to be between 1.1 and 2.6 months (45,(132)(133)(134). Of course, these patients are heavily selected, as patients of good PS and without comorbidities are generally treated with single or combination chemotherapies.…”

Section: As a Prognostic Biomarkermentioning

confidence: 99%

Prognostic Impact of Promoter-Hypermethylated Sfrp1 in Pancreatic Ductal Adenocarcinoma: A Blood-Based Biomarker Study

Stubbe

View full text Add to dashboard Cite

Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study

Cited by 6 publications

References 17 publications

Ancistrolikokine E₃, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

Ancistrolikokine E₃, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

miR-203a-3p and MMP-2 protein are highly expressed in circulating tumor cells from patients with pancreatic carcinoma

Prognostic Impact of Promoter-Hypermethylated Sfrp1 in Pancreatic Ductal Adenocarcinoma: A Blood-Based Biomarker Study

Contact Info

Product

Resources

About

Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study

Cited by 6 publications

References 17 publications

Ancistrolikokine E3, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

Ancistrolikokine E3, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

miR-203a-3p and MMP-2 protein are highly expressed in circulating tumor cells from patients with pancreatic carcinoma

Prognostic Impact of Promoter-Hypermethylated Sfrp1 in Pancreatic Ductal Adenocarcinoma: A Blood-Based Biomarker Study

Contact Info

Product

Resources

About

Ancistrolikokine E₃, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway

Ancistrolikokine E₃, a 5,8′-Coupled Naphthylisoquinoline Alkaloid, Eliminates the Tolerance of Cancer Cells to Nutrition Starvation by Inhibition of the Akt/mTOR/Autophagy Signaling Pathway